Navigation Links
Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer
Date:12/10/2010

WALTHAM, Mass., Dec. 10, 2010 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas.

The following poster discussions are being presented:

  • "A Combination of HDAC Inhibitor Entinostat (MS-275), All Trans Retinoic Acid (ATRA) and Chemotherapy Drug(s) Causes Regression of Established Xenografts of Triple Negative Breast Cancer" December 9, 2010 from 5:30 to 7:30 PM CT by Nguyen K. Nguyen from Johns Hopkins University School of Medicine
  • "HDAC Inhibitor Entinostat Restores Responsiveness of Letrozole Resistant MCF-7Ca Xenografts to AIs through Modulation of Her-2" December 10, 2010 from 5:30 to 7:30 PM CT by Gauri J. Sabnis, Ph.D. from the University of Maryland School of Medicine

  • "These promising results in predictive animal models provide important insight into the molecular mechanisms by which entinostat can target resistance pathways in breast cancer," said Joanna Horobin, M.D., president and chief executive officer of Syndax. "In the phase 2 ENCORE 303 study presented at ASCO, we showed that the addition of entinostat could halt disease progression emerging on treatment with all of the commercially available aromatase inhibitors. Dr. Sabnis' work provides an elegant hypothesis supporting our clinical findings. We are optimistic that our ongoing ENCORE 301 study, a double-blind, randomized, placebo-controlled phase 2 study of entinostat in combination with the aromatase inhibitor exemestane, will provide further evidence supporting the clinical benefit and tolerability of entinostat in postmenopausal women with progressing metastatic breast cancer. We expect
    '/>"/>

    SOURCE Syndax Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
    2. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
    3. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
    4. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
    5. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
    6. Access Pharmaceuticals Reports Significant Third Party Payer Reimbursement Progress for MuGard
    7. Lotus Pharmaceuticals Announces Update on Land in Inner Mongolia
    8. Reportlinker Adds Global Generic Pharmaceuticals Industry Report
    9. Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study
    10. Data from Phase 2 Study of Alder Biopharmaceuticals Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer
    11. Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... Calif. , Oct 22, 2014 Antigen ... Irvine, California , announced the receipt of ... Business Innovation Research award (SBIR) from the National Institute of Dental ... fund the development of a Pan-HIV Protein Microarray Chip, ... HIV-1 and HIV-2 subtypes and aid in the development ...
    (Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical announced ... received 510 (k) OTC clearance by the U.S. Food ... to be marketed over the Internet for: the ... spasms; and minor strains and sprains . ... AVACEN 100 (MSRP $2495) is a sophisticated medical device ...
    (Date:10/22/2014)... DIEGO , Oct. 21, 2014   ... today the latest genomics research centers to purchase ... Salk Institute, the National Cancer Institute (NCI), NIH ... Sequencing Center). Before Irys, obtaining a comprehensive view ... next generation sequencing (NGS) does not deliver the ...
    Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
    ... Inc. (Nasdaq: NUVA ), a medical device company ... for the spine, announced today that Kevin O,Boyle, Chief ... the Oppenheimer 20th Annual Healthcare Conference at The Waldorf ... November 3, 2009. , A live webcast of the ...
    ... your stomach, relieve your wallet , YONKERS, N.Y., Oct. ... us may suffer from occasional heartburn, a new Best Buy Drugs ... don,t need an expensive drug like Nexium, the "purple pill," for ... to identify "Best Buys" based on safety, effectiveness, and price for ...
    Cached Medicine Technology:NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference 2NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference 3Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 2Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 3
    (Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
    (Date:10/22/2014)... Cheap Hosting USA is among the most distinguished review ... that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best cheap ... , “iPower is one of the most reliable hosting ... of useful products for new and old clients. What’s ... and a number of features which will appeal to ...
    (Date:10/22/2014)... 22, 2014 Losing Weight Your Body’s Way ... staring you in the face, it certainly can be difficult ... your body an extra favor by doing it the healthy ... diets. Instead, listen to your body, exercise regularly, and choose ... essential to losing weight; you need to exercise more and ...
    (Date:10/22/2014)... 22, 2014 Lintelus, Inc., an event ... President of Sales, will be speaking on the subject ... Expo on October 28, at the Holiday Inn in ... booth as well as a Tech Demo at 12:45pm, ... create a more engaging event experience. , The Annual ...
    (Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
    Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
    ... length ratio (2D:4D) is a trait known for its ... fourth digits; in women, these fingers tend to be ... intriguing hormonal connections, including higher prenatal testosterone levels, lower ... this ratio has also been linked to athletic and ...
    ... 2, 2008) Athanasios Zavras began receiving messages from ... osteoporosis meds to bone death in the jaw. A ... taking these drugs to postpone dental work, fearing that ... Thats when Zavras, an associate professor in the Harvard ...
    ... Adverse drug events are more common in older adults ... differently by these drugs than their younger counterparts. A ... clinicians, published in American Family Physician, summarizes steps that ... overuse, misuse, and underuse of medication in older adults. ...
    ... testosterone levels who received testosterone supplementation increased lean body mass ... no improvement in mobility or cognition compared with men who ... the January 2 issue of JAMA. , Male aging ... levels of testosterone, occurring to a greater extent in some ...
    ... Catathrenia, or sleep related groaning, is an uncommon ... successfully treated with continuous positive airway pressure (CPAP), according ... of the journal SLEEP. , The study, authored by ... consecutive female patients between the ages of 20 and ...
    ... Forest University Baptist Medical Center suggests that a three-drug ... glioblastoma multiforme (GBM), a type of brain tumor with ... been developed, and the team is working on the ... cells and spare healthy brain., Waldemar Debinski, M.D., Ph.D., ...
    Cached Medicine News:Health News:The risk of osteoarthritis and index to ring finger length ratio 2Health News:The risk of osteoarthritis and index to ring finger length ratio 3Health News:Oral osteoporosis meds appear to reduce the risk of jaw degradation 2Health News:Tips to prevent adverse drug events in older adults 2Health News:Tips to prevent adverse drug events in older adults 3Health News:Testosterone supplementation for older men appears to have limited benefit 2Health News:New study in the journal Sleep finds that catathrenia can be successfully treated with CPAP 2Health News:New study in the journal Sleep finds that catathrenia can be successfully treated with CPAP 3Health News:Research suggests new treatment suitable for all patients 2Health News:Research suggests new treatment suitable for all patients 3
    System, English (Continental cord), 230 VAC....
    Micro-mini fiber optic light....
    Xenon technology achieves a higher efficiency than halogen light sources. Consequently they provide more light....
    The 300W effective dual light source has quality xenon performance....
    Medicine Products: